Pasithea Therapeutics Corp. Common Stock (KTTA) is a publicly traded Healthcare sector company. As of June 15, 2026, KTTA trades at $0.59 with a market cap of $19.75M and a P/E ratio of -0.20. KTTA moved +0.00% today. Year to date, KTTA is -54.18%; over the trailing twelve months it is -28.71%. Its 52-week range spans $0.28 to $4.39. Analyst consensus is buy with an average price target of $3.00. Rallies surfaces KTTA's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
1 analysts cover KTTA: 0 strong buy, 1 buy, 0 hold, 0 sell, and 0 strong sell. The consensus rating is buy. The average price target is $3.00.
| Metric | Value |
|---|---|
| Price | $0.59 |
| Market Cap | $19.75M |
| P/E Ratio | -0.20 |
| EPS | $-2.91 |
| Dividend Yield | 0.00% |
| 52-Week High | $4.39 |
| 52-Week Low | $0.28 |
| Volume | 24.12K |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $-20.43M |
| Gross Margin | 0.00% |
1 analysts cover KTTA: 0 strong buy, 1 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $3.00.